Search
Atezolizumab
go.drugbank.com/drugs/DB11595ApprovedInvestigationalAtezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot ...
Prochlorperazine
go.drugbank.com/drugs/DB00433ApprovedInvestigationalVet approved[L6637] Prochlorperazine was first developed in the 1950s [L6643] and was first approved by the FDA in 1956. … [label] It mainly works by depressing the chemoreceptor trigger zone and blocking D2 dopamine receptors in the brain. It was shown to also block histaminergic, cholinergic and noradrenergic receptors.
MK-1496
go.drugbank.com/drugs/DB12763InvestigationalMK-1496 has been used in trials studying the treatment of Neoplasms and Malignant.
MK-5108
go.drugbank.com/drugs/DB12556InvestigationalMK-5108 has been used in trials studying the treatment of Cancer, Neoplasms, Tumors.
Denufosol
go.drugbank.com/drugs/DB04983InvestigationalDenufosol was an inhaled drug used for the treatment of cystic fibrosis (CF), showing various improvements in lung function during a phase III clinical trial. A new drug application (NDA) was filed with the FDA in 2011, however, the seco...
Primaquine
go.drugbank.com/drugs/DB01087ApprovedInvestigationalAn aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. … It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria.
Adapalene
go.drugbank.com/drugs/DB00210ApprovedInvestigational[A193518] Adapalene has similar efficacy but a superior safety profile compared to tretinoin. … [A193521] [Tazarotene] is more efficacious than adapalene but is designated as pregnancy category X and hence is contraindicated in pregnant women.
Bexarotene
go.drugbank.com/drugs/DB00307ApprovedInvestigationalBexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma.
Enoxaparin
go.drugbank.com/drugs/DB01225ApprovedInvestigationalInitially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies.